COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,046 Articles (22,627 medRxiv, 8,419 bioRxiv)

Most recent first Previous |  Page 1030: Articles 10291-10300  | Next

Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding.
Bertini, S., Alekseeva, A., Elli, S., Pagani, I., Zanzoni, S., Eisele, G., Krishnan, R., Maag, K. P., Reiter, C., Lenhart, D., Gruber, R., Yates, E. A., Vicenzi, E., Naggi, A., Bisio, A., Guerrini, M.
10.1101/2021.12.19.473359 — Posted: 2021-12-21
SARS-CoV-2 vaccine effectiveness and breakthrough infections in maintenance dialysis patients
Manley, H. J., Aweh, G., Hsu, C. M., Weiner, D. E., Miskulin, D., Harford, A. M., Johnson, D., Lacson, E. K.
10.1101/2021.12.20.21268124 — Posted: 2021-12-21
Activity of convalescent and vaccine serum against a B.1.1.529 variant SARS-CoV-2 isolate
Carreno, J. M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A., Kawabata, H., Sominsky, L., Clark, J., Adelsberg, D. C., Bielak, D., Gonzalez-Reiche, A. S., Study Group, P., Srivastava, K., Sordillo, E. M., Bajic, G., van Bakel, H., Simon, V., Krammer, F.
10.1101/2021.12.20.21268134 — Posted: 2021-12-21
Temporal associations of B and T cell immunity with robust vaccine responsiveness in a 16-week interval BNT162b2 regimen
Nayrac, M., Dube, M., Sannier, G., Nicolas, A., Marchitto, L., Tastet, O., Tauzin, A., Brassard, N., Beaudoin-Bussieres, G., Vezina, D., Gong, S. Y., Benlarbi, M., Gasser, R., Laumaea, A., Bourassa, C., Gendron-Lepage, G., Medjahed, H., Goyette, G., Ortega-Delgado, G.-G., Laporte, M., Niessl, J., Gokool, L., Morrisseau, C., Arlotto, P., Richard, J., Tremblay, C., Martel-Laferriere, V., Finzi, A., Kaufmann, D. E.
10.1101/2021.12.18.473317 — Posted: 2021-12-21
Sentimental Tweets Classification of Symptomatic COVID 19
P, T.
10.1101/2021.12.15.472745 — Posted: 2021-12-21
Epidemiology study of SARS-CoV-2 pandemic in India, the first and second wave
Chaudhuri, D., Datta, J., Majumder, S., Giri, K.
10.1101/2021.12.20.21268016 — Posted: 2021-12-21
The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors
Alugubelli, Y. R., Geng, Z. Z., Yang, K., Shaabani, N., Khatua, K., Ma, X. R., Vatansever, E. C., Cho, C.-C., Ma, Y., Blankenship, L., Yu, G., Sankaran, B., Li, P., Allen, R., Ji, H., Xu, S., Liu, W. R.
10.1101/2021.12.18.473330 — Posted: 2021-12-21
Superior immunogenicity and effectiveness of the 3rd BNT162b2 vaccine dose
Lustig, Y., Gonen, T., Meltzer, L., Gilboa, M., Indenbaum, V., Cohen, C., Amit, S., Jaber, H., Doolman, R., Asraf, K., Rubin, C., Fluss, R., Mendelson, E., Freedman, L., Regev-Yochay, G., Kreiss, Y.
10.1101/2021.12.19.21268037 — Posted: 2021-12-21
Bamlanivimab reduces nasopharyngeal SARS-CoV-2 RNA levels but not symptom duration in non-hospitalized adults with COVID-19
Chew, K. W., Moser, C., Daar, E. S., Wohl, D. A., Li, J. Z., Coombs, R., Ritz, J., Giganti, M., Javan, A. C., Li, Y., Malvestutto, C., Klekotka, P., Price, K., Nirula, A., Fischer, W., Bala, V., Ribeiro, R., Perelson, A. S., Fletcher, C. V., Eron, J. J., Currier, J. S., Hughes, M. D., Smith, D. M.
10.1101/2021.12.17.21268009 — Posted: 2021-12-21
Comparative effectiveness of the BNT162b2 vs ChAdOx1 vaccine against Covid-19
Xie, J., feng, s., Li, X., Gea Mallorqui, E., Prats-Uribe, A., PRIETO-ALHAMBRA, D.
10.1101/2021.12.18.21268039 — Posted: 2021-12-21

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).